The construction of large-scale peptidomimetic libraries for drug screening of various neurological diseases is of great significance for the treatment of neurological diseases. CD BioSciences provides peptidomimetic library construction and drug screening services for a variety of neurological diseases, assisting global customers in basic research and drug discovery on neurological treatments.
Overview of Neurological Diseases
Structural, biochemical, or electrical abnormalities of the brain, spinal cord, or other nerves can lead to a range of neurological symptoms, including paralysis, muscle weakness, poor coordination, sensory loss, seizures, psychosis, pain, and altered levels of consciousness. At present, more than 600 neurological diseases have been found in the world. Neurological diseases and their sequelae affect as many as 1 billion people in the world.
Fig. 1 The type I interferon response and neurological disease. (McGlasson, et al., 2015)
Advantages of Peptidomimetic Drugs
The specific causes of nervous system problems vary, but may be due to genetics, congenital anomalies, infections, etc. Because the pathogenesis is ambiguous, it is difficult to truly treat effectively, and the medical community is working to find new drugs for the treatment of nervous system diseases. Peptide-mimetic drugs of biologically active proteins have attracted widespread attention due to their good efficacy, low molecular weight, low side effects, and better membrane penetration.
Our Services
The design and synthesis of peptidomimetics can facilitate better barrier penetration and undoubtedly have great potential in neurotherapeutic drug discovery. In CD BioSciences, we are able to use our advanced PepDomTM platform to construct high-throughput peptidomimetic screening libraries to provide drug screening services for a variety of neurological diseases based on cell models.
The types of neurological disease we focus on include, but are not limited to:
| Type of Neurological Disease |
Examples |
| Peripheral Neuropathy |
Facial Neuritis, Cervical Spondylosis, Neuralgia |
| Spinal Cord Disorder |
Acute Myelitis, Spinal Cord Compression, Syringomyelia |
| Cerebrovascular Disease |
Cerebral Infarction, Cerebral Hemorrhage, Intracranial Venous Thrombosis, Vascular Dementia |
| Central Nervous System Infectious Disease |
Encephalitis, Meningitis, Neurosyphilis, Cerebral Parasitic Disease |
| Extrapyramidal Disease |
Parkinson's Disease, Hepatolenticular Degeneration, Chorea |
| Demyelinating Disease |
Multiple Sclerosis, Acute Disseminated Encephalomyelitis |
| Neuromuscular Junction Disease |
Myasthenia Gravis, Progressive Muscular Dystrophy, Periodic Paralysis, Polymyositis |
| Neurodegenerative Disease |
Motor Neuron Disease, Alzheimer's Disease, Multiple System Atrophy |
| Congenital Disorder |
Cerebral Palsy, Congenital Hydrocephalus |
| Genetic Disorder |
Hereditary Ataxia, Peroneal Muscular Dystrophy |
| Neurosis |
Hysteria, Anxiety, Neurasthenia, Phobia, Hypochondriasis, Depressive Neurosis |
| Epilepsy |
Generalized Epilepsy, Focal Epilepsy |
Our Service Processes
 |
Design of peptidomimetics: Design peptidomimetics according to the customer's specific project requirements, such as sequence, length, conformation, etc. |
 |
Construction of peptidomimetic library: Use our PepDomTM platform to construct a high-capacity random peptidomimetic library with a library capacity of up to 1012. |
 |
Incubation peptidomimetic library: According to the type of disease, select the appropriate cell model (patient source/animal source, etc.) to co-incubate with the library. |
 |
Screening of peptidomimetics: Select the peptidomimetic compounds that work best with cell models for amplification, isolation and purification. |
 |
Verification results: Further verify the therapeutic effect of peptidomimetic compounds according to project requirements, including drug efficacy evaluation, stability analysis, bioavailability evaluation, etc. |
 |
Deliverables: Provide data related to peptidomimetic drug screening services and project achievement reports. |
By building a high-throughput peptidomimetic screening platform, CD BioSciences is committed to screening peptidomimetic drugs for the treatment of various neurological diseases. If you are interested in any aspect of peptidomimetic development for neurological disease treatment, please contact us for the best solution.
References
- McGlasson, S., Jury, A., Jackson, A., & Hunt, D. (2015). Type I interferon dysregulation and neurological disease. Nature Reviews Neurology, 11(9), 515–523.
- Egleton, R. D., & Davis, T. P. (1997). Bioavailability and Transport of Peptides and Peptide Drugs into the Brain. Peptides, 18(9), 1431–1439.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
